专利检索 ap:("INST ANTIBODIES CO LTD") AND inv:"MATSUDA KAZUKI" 第 1 页

1.

发明公开
METHOD OF CLASSIFYING ANTIGEN, METHOD OF IDENTIFYING ANTIGEN, METHOD OF OBTAINING ANTIBODY OR ANTIBODY SET, METHOD OF CONSTRUCTING ANTIBODY PANEL AND ANTIBODY OR ANTIBODY SET AND USE OF THE SAME 有权
标题翻译：分类程序的抗原，一种识别抗原，方法用于获得抗体面板施工和抗体或抗体SETS及其用途抗体或抗体SET，方法

公开(公告)号：EP2078732A4

公开(公告)日：2010-07-28

申请号：EP07790510

申请日：2007-07-09

申请人： INST ANTIBODIES CO LTD

发明人： SUGIOKA ATSUSHI , SUGIURA MOTOTAKA , AKAHORI YASUSHI , HAYASHI NOBUHIRO , TAKASAKI AKIHIKO , MORITA MIWA , KUROSAWA GENE , SUMITOMO MARIKO , TSUTSUMI SUSUMU , OGAWA KEIKO , MATSUDA KAZUKI , MURAMATSU CHIHO , SATOU NORIKO , AZUMA MASACHIKA , UKAI YOSHINORI , SUZUKI KAZUHIRO , KUROSAWA YOSHIKAZU , TANAKA MIHO , SHIRAISHI MAMORU

IPC分类号： C07K16/28 , C12N15/09 , C12Q1/02 , G01N33/574

CPC分类号： C07K16/30 , C07K16/005 , C07K16/28 , C07K16/2803 , C07K16/2863 , C07K16/2896 , C07K16/303 , C07K16/32 , C07K16/40 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C12N15/1138 , C12N2310/14 , G01N33/57492 , G01N33/6854

2.

发明公开
ANTI-IgSF4 ANTIBODY AND UTILIZATION OF THE SAME 有权
标题翻译： ANTI-IGSF4抗体及其用途

公开(公告)号：EP1860119A4

公开(公告)日：2009-04-15

申请号：EP06714335

申请日：2006-02-22

申请人： INST ANTIBODIES CO LTD , KUROSAWA YOSHIKAZU

发明人： AKAHORI YASUSHI , SUGIOKA ATSUSHI , HAYASHI NOBUHIRO , TAKASAKI AKIHIKO , SUZUKI KAZUHIRO , MORITA MIWA , KUROSAWA YOSHIKAZU , IBA YOSHITAKA , SUMITOMO MARIKO , TSUTSUMI SUSUMU , OGAWA KEIKO , MATSUDA KAZUKI , MURAMATSU CHIHO , TAKAHASHI NOBUHIRO , FUJIYAMA SARI , AZUMA MASACHIKA , UKAI YOSHINORI , MORISHITA KAZUHIRO

IPC分类号： C07K16/28 , A61K39/00 , A61P35/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12Q1/02 , G01N33/15 , G01N33/50

CPC分类号： C07K16/303 , A61K2039/505 , C07K16/2803 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/622 , C07K2317/732 , C07K2319/00 , G01N33/57426 , G01N33/57438

摘要： It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, an ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.